Our data also provide a rationale to assess whether Poly(ADP-ribose) polymerase (PARP) inhibitors would increase chemotherapy efficacy in lung cancer patients with abnormal MSH2 or BRCA1 content, by a synthetic lethality mechanism. The gene discussed is MSH2; the disease is lung carcinoma.